Passa al contenuto
Merck

Documenti fondamentali

Visualizza tutta la documentazione

Vai a

L109

Lorglumide sodium salt

solid

Sinonimo/i:

(±)-4-[(3,4-Dichlorobenzoyl)amino]-5-(dipentylamino)-5-oxopentanoic acid sodium salt, CR 1409

Autenticati per visualizzare i prezzi organizzativi e contrattuali.

Scegli un formato

Cambia visualizzazione
Taglio della confezioneSKUDisponibilitàPrezzo
50 mg
Per conoscere la disponibilità, visualizza il carrello
CHF 180.00
CHF 153.00

Informazioni su questo articolo

Formula empirica (notazione di Hill):
C22H31Cl2N2NaO4
Numero CAS:
1021868-76-7
Peso molecolare:
481.39
NACRES:
NA.32
PubChem Substance ID:
24278098
UNSPSC Code:
12352200
MDL number:
MFCD00083183
Form:
solid
Quality level:
100

CHF 153.00

Prezzo di listinoCHF 180.00Risparmia il 15%
Promozione valida solo online
Per conoscere la disponibilità, visualizza il carrello
​
Servizio Tecnico
Hai bisogno di aiuto? Il nostro team di scienziati qualificati è a tua disposizione.
Permettici di aiutarti

form

solid

Quality Level

100

color

white

solubility

45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: >10 mg/mL, H2O: 10 mg/mL, methanol: 28 mg/mL

SMILES string

[Na+].CCCCCN(CCCCC)C(=O)C(CCC([O-])=O)NC(=O)c1ccc(Cl)c(Cl)c1

InChI

1S/C22H32Cl2N2O4.Na/c1-3-5-7-13-26(14-8-6-4-2)22(30)19(11-12-20(27)28)25-21(29)16-9-10-17(23)18(24)15-16;/h9-10,15,19H,3-8,11-14H2,1-2H3,(H,25,29)(H,27,28);/q;+1/p-1

InChI key

JCNPYMDDOUQTBK-UHFFFAOYSA-M

Gene Information

human ... CCKAR(886)

Application

Lorglumide sodium salt has been used as a cck-a (cholecystokinin A) receptor antagonist for peptide determination in rat islet cells.[1] It has been used as a CCK1 inhibitor to check the effect of cck1 (cck-a) and cck2 (cck-b) receptors on cerulein-induced upregulation of egr-1 (early growth response 1) expression in rat pancreatic acinar cells.[2]

Biochem/physiol Actions

Potent and selective non-peptide cholecystokinin (CCKA) receptor antagonist; orally active.[3][4]

Confronta articoli simili

Visualizza il confronto per intero

Mostra le differenze

1 of 1

Questo articolo
SML2236SML0130L119
Lorglumide sodium salt solid

Sigma-Aldrich

L109

Lorglumide sodium salt

L-012 sodium salt ≥98% (HPLC)

Sigma-Aldrich

SML2236

L-012 sodium salt

Loxiglumide ≥97% (HPLC)

Sigma-Aldrich

SML0130

Loxiglumide

L-703,606 oxalate salt hydrate solid

Sigma-Aldrich

L119

L-703,606 oxalate salt hydrate

form

solid

form

powder

form

powder

form

solid

Quality Level

100

Quality Level

-

Quality Level

100

Quality Level

100

solubility

45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: >10 mg/mL, methanol: 28 mg/mL, H2O: 10 mg/mL

solubility

H2O: 2 mg/mL, clear

solubility

DMSO: ≥5 mg/mL

solubility

DMSO: >10 mg/mL, 45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 11 mg/mL, H2O: slightly soluble <2 mg/mL

color

white

color

yellow to orange

color

white to beige

color

white

Gene Information

human ... CCKAR(886)

Gene Information

-

Gene Information

-

Gene Information

human ... TACR1(6869)

Classe di stoccaggio

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
BCBW5189
BCBW1425
BCBV9486
SLBG5165V
SLBB0576V

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

G L Edwards et al.
Annals of the New York Academy of Sciences, 897, 192-197 (2000-02-17)
Ingestion of food and fluid stimulates release of a number of peptides from the gastrointestinal system. These peptides are recognized to act as neurotransmitters/neuromodulators and act at both peripheral and central receptors. Many studies indicate that these peptides are important
H W Suh et al.
Peptides, 16(7), 1229-1234 (1995-01-01)
Various doses of sulfated cholecystokinin octapeptide (CCK-8s) injected intracerebroventricularly (ICV) alone did not show any antinociceptive effect. CCK-8s (0.01-1 ng) pretreated ICV for 10 min dose-dependently attenuated the inhibition of the tail flick response induced by ICV-administered morphine (2 micrograms).
M D'Amato et al.
British journal of pharmacology, 102(2), 391-395 (1991-02-01)
1. Three recently described non-peptide cholecystokinin (CCK) antagonists (devazepide, lorglumide, loxiglumide) have been studied for their antagonism of the contraction to cholecystokinin-octapeptide (CCK-OP) in human alimentary muscle and guinea-pig intestine. 2. Each antagonist caused a concentration-dependent inhibition of the contraction
Visualizza tutti i documenti correlati

Numero articolo commerciale globale

SKUGTIN
L109-250MG04061832677101
L109-50MG04061832677118

Questions

Reviews

No rating value

Active Filters